Chinese Medicine Sheng Jing Decoction Alleviates Oligoasthenospermia by Modulating PI3K/Akt and MAPK Signaling Pathways

Mouse study: a team's proprietary herbal decoction improved sperm count and motility after drug-induced damage, via PI3K/Akt and MAPK pathways

Journal: Phytomedicine | Published: 2026-05-22 | Type: Animal Study | PMID: 42208102 Authors: Gao Sheng, Sun Fei et al. (Sir Run Shaw Hospital, Zhejiang University; Institute of Reproductive Medicine, Nantong University) Funding/COI: Funding not disclosed. Authors declare no competing financial interests — but the lead institution developed SJD themselves.

Summary

Researchers at Zhejiang University tested their own multi-herb formulation, Sheng Jing Decoction (SJD), on mice whose sperm production was chemically wrecked using triptolide, a compound extracted from a Chinese herb known to damage spermatogenesis. SJD reversed much of that damage in the triptolide mice: sperm concentration, motility, and testicular tissue architecture all improved relative to untreated damaged controls. The proposed mechanism runs through two major cell-survival and stress-response pathways, PI3K/Akt and MAPK, both upstream-regulated by Ras.

Claims

• SJD significantly improved sperm concentration and motility in triptolide-induced OAT mice vs. untreated OAT controls (no absolute values reported in abstract)
• Transcriptomic analysis identified differentially expressed genes in pathways related to spermatogenesis and sperm motility, described as consistent with the phenotypic improvements
• SJD reduced testicular apoptosis, oxidative stress markers, and inflammatory markers in TP-treated mice
• Western blot and RT-qPCR confirmed modulation of PI3K/Akt and MAPK pathway components
• Ras identified as a common upstream regulator of both affected pathways

Study Quality

This is a mouse mechanistic study, not a clinical trial. The OAT model uses triptolide — a chemotherapy-adjacent compound — to chemically ablate spermatogenesis. That's a reproducible, well-characterized model, but drug-induced OAT in mice is not the same disease process as idiopathic or varicocele-related OAT in humans. The study uses reasonable methodology (CASA for sperm analysis, H&E histology, transcriptomics, Western blot, RT-qPCR), and including transcriptomic data to support mechanistic claims is a genuine strength for an animal study. However, the abstract reports no absolute numbers — no sperm concentration figures, no motility percentages, no fold-changes for pathway proteins — making independent evaluation of effect magnitude impossible from this summary alone.

SJD's chemical composition was characterized by UHPLC, which is appropriate for a multi-herb formula, but the specific active constituents driving the observed effects remain unidentified. "It's a 20-ingredient decoction that modulates two major signaling pathways" is a mechanistic claim without a tractable therapeutic handle.

Red Flags

• Mouse-only, no human data. Every finding is in a chemically induced model; translation to human OAT is entirely speculative.
• The researchers tested their own formula. SJD was "developed by our team." No financial COI declared, but the intellectual stake is real. Independent replication has not occurred.
• No comparison to standard treatments. The study compares SJD to a damaged-but-untreated control, not to clomiphene, antioxidant therapy, or any existing intervention.
• Triptolide model limitations. Triptolide causes rapid, severe spermatogenic collapse; reversing drug toxicity is mechanistically distinct from treating most clinical OAT.
• No absolute outcome numbers in the abstract. "Significantly improved" without effect sizes is uninformative.
• No pharmacokinetic or bioavailability data. Whether the active constituents of SJD survive human GI transit and reach testicular tissue is unaddressed.
• Funding not disclosed. For a paper on a proprietary formulation, this is a meaningful omission.

Strengths

• Mechanistic depth: transcriptomics combined with protein-level validation (Western blot + RT-qPCR) makes the pathway claims more than correlational
• UHPLC characterization of SJD's chemical composition adds reproducibility
• Multi-endpoint evaluation (sperm parameters + histology + apoptosis + oxidative stress + inflammation) provides a fuller picture than sperm counts alone
• Ras as a common upstream node for both MAPK and PI3K/Akt is a coherent mechanistic hypothesis

Verdict

A competent mouse study with one large structural problem: the team testing their own proprietary formula found their formula works. That's not fraud — it's how preclinical development starts — but without independent replication and without human data, this paper establishes mechanistic plausibility, nothing more. The pathway biology (PI3K/Akt, MAPK, Ras) is real and well-studied in spermatogenesis; the evidence that SJD modulates it in triptolide-damaged mice is credible. The leap from "reversed drug toxicity in mice" to "complementary therapeutic strategy for male infertility" in the conclusion is longer than the data supports. File under: interesting early signal, watch for phase I data.